Dr Andrew Davies (University of Southampton, Southampton, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical importance of molecularly distinct subtypes of DLBCL.
ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
17th February 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?